The MSRB3 antibody is designed to target methionine sulfoxide reductase B3 (MSRB3), an enzyme critical for repairing oxidative damage to proteins. Methionine residues in proteins are susceptible to oxidation, forming methionine sulfoxide, which can impair protein function. MSRB3 specifically reduces methionine-R-sulfoxide back to methionine, restoring protein activity and contributing to cellular antioxidant defense. This enzyme localizes to the mitochondria and endoplasmic reticulum, where it plays a role in maintaining redox homeostasis.
MSRB3 is implicated in various physiological and pathological processes, including hearing loss, neurodegenerative diseases, and cancer. Mutations in the MSRB3 gene are linked to human deafness, highlighting its importance in cochlear function. In cancer, MSRB3 expression may influence tumor progression by modulating oxidative stress responses.
Antibodies against MSRB3 are valuable tools for studying its expression, subcellular localization, and interaction partners. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research using MSRB3 antibodies has advanced understanding of its tissue-specific roles, regulatory mechanisms, and potential as a therapeutic target in oxidative stress-related disorders. However, antibody specificity and validation remain essential considerations to ensure accurate experimental outcomes in diverse biological contexts.